In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.

Episode Timestamps;

00:00 Introduction and Welcome

00:27 Rick's Background and Project Overview

02:31 Client Team Introductions

05:32 Collaboration and Challenges

13:29 Defining the Mechanism and Market Positioning

23:52 Communication and Alignment

27:48 Navigating Internal and External Communication

33:15 Launch, Reflections, and Lessons Learned

41:14 Final Thoughts and Acknowledgements

Keep up with the guests;

• Robyn Blackburn  - Director Global Commercial Strategy CAR-T at Kite Pharma
  • https://www.linkedin.com/in/robyn-blackburn-805b8b13/
• Jayne Butler - Director of Strategic Initiatives at Fingerpaint Branding
  • https://www.linkedin.com/in/jaynebutler/
• Tracey Sacco - Former SVP Global Strategic Marketing at Acceleron
  • https://www.linkedin.com/in/tracey-sacco-53 2a034/
• Rick Ritacco - Head of Growth and Innovation
  • https://www.linkedin.com/in/rritacco/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.

Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease.

They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine.

This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine.

00:00 Introduction and Guest Welcome

01:16 Sekar Kathiresan's Early Life and Education

03:19 Founding Verve and Transition to Entrepreneurship

05:35 The Science Behind Verve's Mission

10:27 Challenges and Breakthroughs in Gene Editing

20:05 Regulatory Hurdles and First Human Trials

25:11 Ethical Considerations in Gene Editing

27:06 Introduction to Drug Delivery and Ethical Considerations

27:51 Historical Context and Pioneers in Medical Procedures

28:35 Commercial and Ethical Challenges in Medicine

29:32 Innovations in Cardiovascular Treatments

32:49 The Role of Gene Editing in Long-term Health

37:55 Strategic Partnerships and Industry Insights

45:08 Reflections on the US Medical Ecosystem

48:54 Conclusion and Future Outlook

Keep up with Sekar Kathiresan;

LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/

Website: https://www.lilly.com/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.

The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation!

00:00 Welcome to Idea Collider

00:04 Introducing Alex Telford

01:59 Alex's Journey from UCL to Convoke Bio

05:29 The Mission and Work of Convoke Bio

07:57 Challenges in Pharma Decision Making

14:05 The Role of AI in Pharma

18:26 Knowledge Management and AI

27:58 Staying Updated in the Fast-Moving AI Field

30:25 AI's Impact on Industry Economics

31:38 AI in Clinical Trials and Drug Development

35:56 China's Role in Drug Discovery

39:24 Neuroscience and AI: Blurring the Lines

46:05 Future Predictions in Pharma

51:20 Addressing Cognitive Bias in Pharma

53:13 Concluding Thoughts and Future Directions

Keep up with Alex Telford;

LinkedIn: https://www.linkedin.com/in/alexander-telford/

Website: atelfo.github.io

X: https://twitter.com/atelfo

Substack: atelfo.substack.com

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation.

00:00 Introduction and Guest Welcome

00:25 Christian Rommel's Journey in Oncology

03:02 The Importance of Collaboration in Innovation

05:16 Balancing Risk and Reward in Drug Development

18:07 The Role of AI and Data in Modern R&D

22:33 Partnerships and External Learning

26:16 Balancing Legacy and Innovation in Biotech

27:18 Global Expansion and Leadership Diversity

27:27 Courage in Biotech Management

27:54 Inspiration from Roche Genentech

30:26 Commitment to Product Supply and Market Readiness

32:23 Challenges of Global Launches

35:53 Emerging Trends in Pharma: AI and Genetic Medicines

42:20 Decision-Making in Pharma

47:30 Reflections on Academic and Professional Journey

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Christian Rommel;

LinkedIn: https://www.linkedin.com/in/christian-rommel/

Website: https://www.bayer.com/en/innovation/science-research-and-innovation

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies.

00:00 Introduction and Guest Background

00:56 Founding Thebans and Career Highlights

01:43 Leadership at Merck and J&J

02:18 Innovative Approaches at Parabilis Medicines

04:09 Defining and Tackling Undruggable Targets

09:27 Multivalent Drug Design and Bispecifics

13:53 AI and Data Science in Drug Development

19:28 Building and Leading World-Class Teams

25:41 The Importance of Holding Conviction as an Entrepreneur

26:25 Learning from Setbacks in the Biotech Industry

30:10 Challenges and Innovations in Drug Development

32:28 Navigating the Ups and Downs of the Biotech Industry

36:02 The Mission and Future of Parabilis

40:35 Personal Reflections and Advice for Entrepreneurs

46:46 Book Recommendations and Closing Thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Mathai Mammen;

LinkedIn: https://www.linkedin.com/in/mathai-mammen/

Website: https://parabilismed.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative.

00:00 Introduction and Guest Welcome

00:59 Early Career and Passion for Medicine

02:09 Transition to Industry and GSK Experience

04:50 Building Successful Organizations

07:42 Innovative Models in Pharma

19:03 Joining Candel Therapeutics and Vision for the Future

25:15 Transforming Cancer Treatment

27:24 Challenges in Biotech Market

28:45 Strategic Decisions and Prioritization

31:39 Collaborations and External Partnerships

33:07 Innovative Approaches and Future Prospects

44:23 Leadership and Personal Insights

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Paul Peter Tak;

LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools. 

With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.

Chapter Summaries;

00:00 Introduction and Guest Welcome

00:27 Susan Galbraith's Career Journey

02:37 Defining Success in Oncology R&D

05:01 Early Phase Drug Development

07:09 Digital Health and Patient Experience

12:37 Global Collaboration and Innovation

15:05 AI and Future of Oncology

28:08 Diversity and Inclusion in Clinical Trials

33:46 Mentorship and Career Advice

37:45 Challenges and Future Outlook in Oncology

42:06 Closing Remarks and Call to Action

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Susan Gabraith;

• LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk

Follow Mike Rea On;

• Website: https://www.ideapharma.com/
• X: https://x.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. 

Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery.
 

Chapter Summaries;

00:00 Introduction to John Maraganore: Biotech Trailblazer

01:11 John's Early Life and Education

03:09 Joining Alnylam and the RNAi Revolution

04:56 Challenges and Successes at Alnylam

06:47 Current Biotech Funding Environment

08:17 Global Competition and US Leadership in Biotech

10:25 The Importance of In-Person Collaboration

12:01 Overcoming Drug Delivery Hurdles

15:21 Maintaining an Entrepreneurial Spirit in Biotech

17:00 Balancing Science and Business in Decision Making

20:27 Strategic Partnerships in Biotech

23:36 The Role of Biotech in Global Challenges

26:25 Advocating for Policy Changes in Biotech

30:41 Mentoring the Next Generation of Biotech Leaders

32:35 Future Frontiers in Biotech Innovation

36:08 John's Vision for the Future of Biomedicine

37:18 Communicating Innovation and Leadership

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with John Maraganore;

• LinkedIn: https://www.linkedin.com/in/john-maraganore/

Follow Mike Rea On;

• Website: https://www.ideapharma.com/
• X: https://x.com/ideapharma
• LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to another episode of Idea Collider with your host, Mike Rea. 

In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics. 

Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape. 

Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future. 

Chapter Summaries 

[0:00:21] Introduction to today's guest, Dr. Nedim Pipic 

[0:04:23] Discussion on Innovation and Growth Mindset 

[0:06:44] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health 

[0:08:25] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs 

[0:14:39] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms 

[0:16:39] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture 

[0:18:52] Discussion on Innovation and R&D in Pharmaceutical Industry 

[0:20:22] Driving Innovation and Culture in a Private Pharmaceutical Company 

[0:23:41] Insights on Innovation and Transformation 

[0:25:46] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation 

[0:27:04] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation 

[0:33:28] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration 

[0:36:06] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability 

[0:37:39] Closing Remarks 

Don't forget to Like, Share, Subscribe, Rate, and Review! 

Keep up with Dr. Nedim Pipic; 

● LinkedIn: https://www.linkedin.com/in/nedim-pip... 

● Website: http://www.boehringer-ingelheim.com 

Follow Mike Rea On; 

● Website: https://www.ideapharma.com/ 

● Twitter: https://twitter.com/ideapharma 

● LinkedIn: https://www.linkedin.com/in/bigidea/ 

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ 

Don’t forget to Subscribe, Rate, Review, Like, and Share! 

To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/